Rhythm Biosciences: Half-Year Financial Report and Appendix 4D
Filed with ASX · · 22 pages · English
Rhythm Biosciences Limited Appendix 4D Preliminary final report 7. Audit qualification or review Details of audit/review dispute or qualification (if any): The financial statements have been reviewed and an unqualified conclusion has been issued. 8. Attachments Details of attachments (if any): 9. Signed Dr David Atkins Managing Director Date: 18 February 2026 Rhythm Biosciences Limited Corporate D
Rhythm Biosciences Limited on 6ix
Story so far
Earlier from Rhythm Biosciences
- Rhythm Bio enters ColoSTAT agreement with 4Cyte Pathology
- ColoSTAT commercial deployment - First physician enrolled
- Rhythm Biosciences Signs Manufacturing Agreement
- Quarterly Activities Report and Appendix 4C
- Enhanced Genetype colorectal cancer risk test released - supports earlier disease detection and ColoSTAT® targeting
Later from Rhythm Biosciences
- Trading Halt
- Exercise of RHYO Options underwritten for $4.5m to $6.0m
- RHY Executes SE Asian Genetype Distribution Agreement
- NATA Accredits ColoSTAT Clinical Testing Service
- First ColoSTAT Clinical Test Sale
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences